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ABSTRACT
Mesenchymal stem cell (MSC) therapy for myocardial injury
has inherent limitations due to the poor viability of MSCs af-
ter cell transplantation. In this study, we directly delivered
Hsp70, a protein with protective functions against stress, into
MSCs, using the Hph-1 protein transduction domain ex vivo
for high transfection efﬁciency and low cytotoxicity. Com-
pared to control MSCs in in vitro hypoxic conditions, MSCs
delivered with Hph-1-Hsp70 (Hph-1-Hsp70-MSCs) displayed
higher viability and anti-apoptotic properties, including Bcl2
increase, reduction of Bax, JNK phosphorylation and cas-
pase-3 activity. Hsp70 delivery also attenuated cellular ATP-
depleting stress. Eight animals per group were used for in
vivo experiments after occlusion of the left coronary artery.
Transplantation of Hph-1-Hsp70-MSCs led to a decrease in
the ﬁbrotic heart area, and signiﬁcantly reduced the apoptotic
positive index by 19.5 6 2%, compared to no-treatment con-
trols. Hph-1-Hsp70-MSCs were well-integrated into the
infarcted host myocardium. The mean microvessel count per
ﬁeld in the infarcted myocardium of the Hph-1-Hsp70-MSC-
treated group (122.1 6 13.5) increased relative to the MSC-
treated group (75.96 10.4). By echocardiography, transplan-
tation of Hph-1-Hsp70-MSCs resulted in additional increases
in heart function, compared to the MSCs-transplanted group.
Our results may help formulate better clinical strategies for
in vivo MSC cell therapy for myocardial damage. STEM CELLS
2009;27:2283–2292
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INTRODUCTION
Mesenchymal stem cells (MSCs) show therapeutic potential
for repair of myocardial infarctions and prevention of post-
infarct congestive heart failure. MSCs produce a variety of
cardio-protective signaling molecules, and have the ability to
differentiate into both myocyte and vascular cell lineages after
transplantation into the infarcted heart [1, 2]. However, poor
viability of transplanted cells is a major limiting factor of cell
therapy. Toma et al. [3] reported a very low survival rate
(<1%) for MSCs transplanted into uninjured mouse hearts at
4 days after transplantation.
Heat shock proteins (Hsps) provide a defense against
stress caused by high temperature, oxidative stress, pressure
overload, and hypoxia/ischemia [4, 5]. A number of protective
functions have been attributed to Hsps, especially Hsp70,
including ion channel repair, redox balance restoration,
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interaction with the nitric oxide-induced protection pathway,
inhibition of proinﬂammatory cytokines, and preventing acti-
vation of the apoptosis pathway [6–11]. Although MSCs
transfected with an anti-apoptotic gene using a retroviral vec-
tor enhanced their therapeutic effectiveness, constitutive
expression of anti-apoptotic genes in MSCs may induce tu-
morigenesis, thereby altering their differentiation capacity and
limiting their clinical application to humans [12–14]. Various
challenges are presented by gene therapy procedures and
genetic manipulation of MSCs using transfection, viral vectors
or microinjection of proteins into cells. These include low
transfection efﬁciency, cytotoxicity associated with chemical
agents, and harmful retroviral transfection [15–17]. In order
to overcome these problems, Protein Transduction Domains
(PTDs), synthesized or identiﬁed in proteins from various spe-
cies, have been shown to deliver therapeutic proteins with
almost 100% efﬁciency into eukaryotic cells both in vitro and
in vivo. In particular, a novel, cell-permeable PTD was identi-
ﬁed from the human transcriptional factor Hph-1. The Hph-1-
PTD has been successfully used to deliver immunosuppressive
proteins in vivo and in vitro for the treatment of various auto-
immune diseases through different administration routes [18].
In this study, Hsp70 was directly delivered into MSCs using
Hph-1-PTD ex vivo. The protective effect of Hph-1-Hsp70 on
MSCs from hypoxia-induced apoptosis and the in vivo thera-
peutic potential of Hph-1-Hsp70-treated MSCs were examined
in myocardial infarction-induced rats.
MATERIALS AND METHODS
Isolation and Culture of MSCs
MSCs were isolated and cultured from the femoral and tibial
bones of donor rats [19]. Bone marrow-derived MSCs were col-
lected from aspirates of the femurs and tibias of 4-week-old
Sprague-Dawley male rats (about 100 g) with 10 ml of MSC
medium consisting of Dulbecco’s modiﬁed Eagle’s medium
(DMEM)-low glucose supplemented with 10% fetal bovine serum
(FBS) and 1% antibiotic-penicillin and streptomycin solution.
Flushed media were centrifuged at 1,600 rpm, 5 minutes and
resuspended in serum-supplemented medium, and loaded onto a
Percoll density gradient before centrifugation at 1,600 rpm, 30
minutes. Mononuclear cells recovered from the middle interface
were washed twice, resuspended in 10% FBS-DMEM, and plated
at 1  106 cells/100 cm2 in ﬂasks. Cultures were maintained at
37C in a humidiﬁed atmosphere containing 5% CO2. After 48 or
72 hours, nonadherent cells were discarded, and the adherent cells
were thoroughly washed twice with phosphate-buffered saline
(PBS). Fresh complete medium was added and replaced every 3
or 4 days for 10 days. To further purify the MSCs, the Isolex
Magnetic Cell Selection System (Baxter Healthcare Corporation,
Irvine, CA, http://www.baxter.com) was used. Brieﬂy, cells were
incubated with M-450 Dynabeads coated with anti-CD34 mono-
clonal antibody. A magnetic ﬁeld was applied to the chamber and
the CD34þ cell-bead complexes were separated magnetically
from the remaining cell suspension, for further culturing of the
CD34 fraction. Cells were harvested after incubation with
0.25% trypsin and 1 mM EDTA for 5 minutes at 37C, replated
in 1  105/100-cm2 plates, and grown for approximately 10 days.
The characteristics of MSCs were demonstrated by immunophe-
notyping. To verify the nature of cultured MSCs, cells were la-
beled for various surface and intracellular markers, and analyzed
by ﬂow cytometry. Cells were harvested, washed with PBS, and
labeled with antibodies against CD14, CD34, CD71, CD90,
CD105 or ICAM-1 conjugated with ﬂuorescein isothiocyanate
(FITC) or Texas red. FITC-conjugated goat anti-mouse IgG and
Texas red-conjugated goat anti-rabbit IgG from Jackson Immu-
noresearch Laboratories (West Grove, PA, USA, http://www.jack-
sonimmuno.com) were used as secondary antibodies. Labeled
cells were assayed by ﬂow cytometry and analyzed with Cell-
Quest Pro Software (BectonDickinson, San Jose, CA, http://
www.bd.com).
Protein Puriﬁcation of Hph-1-Hsp70
The expression plasmid pHph-1-Hsp70 was transformed by heat
shock into BL21-DE3 (ATCC N. 53863). Transformed bacteria
were grown at to OD600 0.7 in LB medium. Protein expression
was induced at 37C with 1 mM IPTG (Gibco BRL, Grand
Island, NY, http://www.invitrogen.com) for 4 hours. Cells were
harvested by centrifugation at 6,000 rpm for 20 minutes and the
pellet was resuspended in binding buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM Imidazole, pH 8.0). Bacteria were soni-
cated 6 seconds on/off for a total time of 8 minutes (Heat sys-
tems, ultrasonic processor XL). After removal of the cell debris
by centrifugation, 0.5 ml of 50% Ni2þ-NTA agarose beads (Qia-
gen, Hilden, Germany, http://www1.qiagen.com) was added to
the clariﬁed cell extract. Agarose bead binding was performed at
4C and the extract was loaded on to poly-Prep chromatography
columns (0.8  4, Bio-Rad Laboratories, Richmond, CA, USA,
http://www.bio-rad.com). Columns were washed with wash buffer
(20 mM Tris-HCl, 500 mM NaCl, 20 mM Imidazole, pH 7.9)
and eluted with 1 ml of elution buffer one (50 mM NaH2PO4,
300 mM NaCl, 250 mM Imidazole, pH 8.0) and elution buffer
two (50 mM NaH2PO4, 300 mM NaCl, 500 mM Imidazole, pH
8.0), followed by passage through a PD-10 desalting column
(Amersham Pharmacia Biotech, Tokyo, Japan, http://
www1.gelifesciences.com).
Hsp70 Delivery into MSCs and
Experimental Hypoxia
MSCs were cultured at 80% conﬂuency and 0.5 lM Hph-1-
Hsp70 was added to the cell culture for 1-hour, followed by incu-
bation in hypoxic conditions for 24 hours. Media used under
hypoxic conditions was 1% FBS-DMEM containing antibiotics
(100 U/ml penicillin and 100 lg/ml streptomycin), which was
degassed and substituted with a gas mixture of 10% CO2, 5% H2,
and 85% N2. The airtight humidiﬁed hypoxic chamber (Anaero-
bic Environment, ThermoForma, Marietta, OH, USA, http://
www.thermo.com) was maintained at 37C and continuously
gassed with N2.
Cell Survival
Cell survival was measured with the PreMix WST-1 Cell Count-
ing System (TAKARA BIO Inc., Shiga, Japan, http://www.ta-
kara-bio.com), which uses a colorimetric assay for cleavage of
the red tetrazolium salt (WST-1) by mitochondrial succinate-tetra-
zolium reductase in viable cells. An increase in enzyme activity
increases the production of formazan dye, and so the quantity of
dye is related directly to the number of metabolically active cells.
Cells (2  104) were seeded into wells of a 96-well culture plate
and incubated under hypoxic conditions after pretreatment with
or without Hph1-Hsp70. WST-1 cell counting reagent was added
directly to the supernatant (10 ll/100 ll growth medium), and
incubated at 37C for 3 hours. Absorbancy of the solubilized
dark red formazan product was determined at 450 nm.
Caspase-3 Activity Assay
MSCs (1  106) were treated with Hph1-Hsp70 and incubated at
37C for 1-hour before inducing apoptosis by exposure to
hypoxic conditions for 24 hours at 37C. Cells were harvested,
and lysates were evaluated for caspase activity with ApopTar-
getTM Capase-3 (BioSource International Inc., Grand Island, NY,
http://www.invitrogen.com) according to the manufacturer’s
instructions. This assay is based on the generation of free DEVD-
pNA chromophores when the provided substrate is cleaved by
caspase-3. Upon substrate cleavage, free pNA light absorbance
was quantiﬁed using a microplate reader at 405 nm.
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Assay of Intracellular ATP Levels
Cellular ATP levels were measured using a commercial luciferase
kit, ViaLight HS (Cambrex, Walkersville, MD, USA, http://
www.cambrex.com) according to the manufacturer’s instructions.
Brieﬂy, 2  104 cells were plated in 96-well luminescence-com-
patible plates. Cells were pretreated with or without Hph1-Hsp70
fusion protein for 1-hour and incubated under hypoxic conditions
for 24 hours. The culture plate was removed from the incubator
and cooled at room temperature for at least 5 minutes, after
which 100 ll of Nucleotide Releasing Reagent was added to each
well. After at least 5 minutes, 20 ll of ATP monitoring reagent
was added to each well and the plate was read immediately. Lu-
minescence was measured by a LS 50B luminometer (Perkin-
Elmer Life and Analytical Sciences, Boston, MA, USA, http://
www.perkinelmer.com).
Immunoblot Analysis
Proteins were separated by 10–12% SDS-PAGE and electrotrans-
ferred to methanol-treated polyvinylidene diﬂouride membranes.
Membranes were blocked with 5% nonfat dried milk in PBS.
After 1-hour at room temperature, membranes were probed over-
night at 4C with mouse polyclonal antibodies against Hsp70,
phospho-JNK, c-Jun N-terminal kinase (JNK), Bcl-2 or Bax
(Santa Cruz Biotechnology, Santa Cruz, CA, http://
www.scbt.com) followed by IgG-peroxidase as secondary anti-
body. Blots were developed using enhanced chemiluminescence
kits (ECL, Amersham Pharmasia Biotech, Tokyo, Japan).
Measurement of Apoptosis by Annexin V Staining
Cells were trypsinized and gently washed with serum-containing
culture medium and PBS, before resuspension in binding buffer
(10 mM HEPES, 140 mM NaCl, 25 mM CaCl2) and incubation
with annexin V-FITC (BD Pharmingen, San Diego, CA, http://
www.bdbiosciences.com/index_us.shtml) and propidium iodide
(PI; Sigma, St. Louis, MO, http://www.sigma.com) at room tem-
perature for 15 minutes. Fluorescence analysis was carried out
using a ﬂow cytometer (Beckman Coulter, Inc., San Diego, CA,
http://www.beckmancoulter.com). In all data included in this
study, forward scatter/side scatter (FSC/SSC) distribution pattern
of cells was detected and analyzed. Annexin V-FITC signals
were detected using an FL1 detector and PI signals were detected
using an FL3 detector.
Induction of Myocardial Infarction
Experiments were conducted in accordance with the International
Guide for the Care and Use of Laboratory Animals. The protocol
was approved by the Animal Research Committee of the Yonsei
University College of Medicine. Under general anesthesia,
8-week-old Sprague-Dawley male rats (about 250 g) were intuba-
ted, and positive-pressure ventilation (180 ml/minute) was main-
tained with room air supplemented with oxygen (2 l/minute)
using a Harvard ventilator. The heart was exposed through a
2-cm left lateral thoracotomy. The pericardium was incised and a
6-0 silk suture (Johnson & Johnson, Langhome, PA, http://
www.jnj.com) was placed around the proximal portion of the left
coronary artery, beneath the left atrial appendage. Ligature ends
were passed through a small length of plastic tube to form a
snare. For coronary artery occlusion, the snare was pressed onto
the surface of the heart directly above the coronary artery and a
hemostat applied to the snare. Ischemia was conﬁrmed by the
blanching of the myocardium and dyskinesis of the ischemic
region. After 60 minutes of occlusion, the hemostat was removed
and the snare released for reperfusion, with the ligature left loose
on the surface of the heart. Restoration of normal rubor indicated
successful reperfusion. Wounds were sutured and the thorax was
closed under negative pressure. Rats were weaned from mechani-
cal ventilation and returned to cages to recover. In sham-operated
rats, the same procedure was executed without tightening the
snare (normal).
MSCs Labeling and Transplantation
MSCs were labeled with DAPI to determine cell viability by add-
ing sterile DAPI solution to the culture medium for 30 minutes
on the day of implantation, at a ﬁnal concentration of 50 lg/ml.
Cells were rinsed six times in PBS to remove unbound DAPI.
Labeled cells were detached with 0.25% (w/v) trypsin and sus-
pended in serum-free medium for grafting. For instant transplan-
tation after surgical occlusion of the left anterior descending cor-
onary artery, MSCs (2.0  105 cells) were suspended in 10 ll
serum-free medium and kept on ice until injection with a
30-gauge needle on a Hamilton syringe at three sites, into ante-
rior and lateral aspects of the viable myocardium bordering the
infarction. There are ﬁve groups of eight rats each used in this
study as follows: Normal, non-ligated sham rat; Control, ligated
but not implanted rat; MSCs, ligated and MSCs implanted rat;
Hph-1-MSCs, ligated and Hph-1 vector only delivered MSCs
implanted rat; Hph-1-Hsp70-MSCs: ligated and Hph-1-Hsp70-
delivered MSCs implanted rat. Then each group was subdivided
three groups of eight rats. One group was injected with DAPI
stained MSCs for determining the survival rate of MSCs after
3 days after implantation. MSCs were implanted into the rest two
groups, one group was used for morphologic analysis at 1 week,
and other for echocardiography at 3 weeks.
Histology and Immunohistochemistry
Transplanted animals were euthanized at 1 week after implanta-
tion and their hearts excised, perfusion-ﬁxed with 10% (v/v) neu-
tral buffered formaldehyde for 24 hours, transversely sectioned
into four comparable sections, and embedded in parafﬁn by rou-
tine methods. Sections of 2 lm were mounted on gelatin-coated
glass slides to allow use of different stains on successive sections
of tissue cut through the implantation area. After deparafﬁnization
and rehydration, the sections were stained with hematoxylin and
eosin (H&E) to assess nuclei, cytoplasm, and connective tissue.
Histological analysis was performed using the manufacturer’s
instructions (Vector Laboratories, Burlingame, CA, http://
www.vectorlabs.com). In brief, excised heart tissues were ﬁxed in
3.7% buffered formaldehyde and embedded in parafﬁn. Tissue
sections of 5 lm were deparafﬁnized, rehydrated and rinsed with
PBS. Antigen retrieval was performed by microwaving for 10
minutes with 10 mM sodium citrate (pH 6.0). Sections were incu-
bated in 3% H2O2 to quench endogenous peroxidase. Sample was
blocked in 2.5% normal horse serum, and incubated in primary
antibody (CD31). Biotinylated pan-speciﬁc universal secondary
antibody and streptavidin/peroxidase complex reagent were used
for the heart sections, which were stained with antibody using a
DAB substrate kit. Counterstaining was with 1% methyl green,
and dehydration progressed with 100% N-butanol, ethanol and
xylene before mounting in VectaMount Medium (Vector Labora-
tories, Burlingame, CA, http://www.vectorlabs.com). Other serial
sections were analyzed with mouse anti-MHC, mouse anti-MLC,
and mouse anti-CTnT obtained from Santa Cruz, and rabbit anti-
connexin 43 and rabbit anti-N-cadherin from Cell Signaling.
FITC-conjugated goat anti-rabbit IgG and Texas red-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch, West Grove,
PA, http://www.jacksonimmuno.com) were used as secondary
antibodies. All images were made using an excitation ﬁlter under
reﬂected light ﬂuorescence microscopy and transferred to a com-
puter equipped with MetaMorph software version 4.6 (Universal
Imaging Corporation, Downingtown, PA, USA, http://www.mole-
culardevices.com/pages/software/metamorph.html).
Determination of Infarct Size
TTC staining was used to assess myocardial tissue viability and
determine the size of the myocardial infarct. The tissue slices
were incubated in a 1% 2, 3, 5-triphenyltetrazolium chloride
(TTC, Sigma, St. Louis, MO, http://www.sigma.com) solution,
pH 7.4, at 37C for 20 minutes. The tissues were ﬁxed in 10%
PBS-buffered formalin overnight at 2–8C. The hearts were
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sectioned transaxially and the size of myocardial infarction was
evaluated as a percentage of the sectional area of the infarcted
tissue of the left ventricle to the sectional area of the whole left
ventricle. Both sides of each TTC-stained tissue slice were photo-
graphed with a digital camera.
Terminal Deoxynucleotidyl Transferase–Mediated
dUTP Nick-End Labeling (TUNEL) Assay
TUNEL Assay was performed according to the manufacturer’s
instructions (Chemicon International Inc., Temecula, CA, http://
www.chemicon.com) on excised heart tissues prepared as
described above. A positive control sample was prepared from a
normal heart section by treating the section with DNase I
(10 U/ml, 10 minutes at room temperature). Sections were
pretreated with 3.0% H2O2, subjected to TdT enzyme for 37
C
for 1-hour, and incubated in digoxigenin-conjugated nucleotide
substrate at 37C for 30 minutes. Nuclei exhibiting DNA
fragmentation were visualized by adding 3,3-diaminobenzidine
(DAB) (Vector Laboratories, Burlingame, CA, http://www.
vectorlabs.com) for 5 minutes. The nuclei of apoptotic cells were
stained dark brown. Lastly, sections were counterstained with
methyl green and sections were observed by light microscopy.
For each group, six slices were prepared and ten different regions
were observed per slice ( 400).
Assessment of Cardiac Function
Transthoracic echocardiographic studies were performed by an
experienced cardiologist blinded to group assignments, at baseline
(before LAD ligation), immediately after LAD ligation (before
treatment) and 3 weeks after cell transplantation (after treatment)
using a GE Vivid Seven ultrasound machine (GE Medical Sys-
tem, Salt Lake City, UT, http://www.gehealthcare.com) with a
10.0 MHz transducer. Rats received general anesthesia and were
placed in the left lateral decubitus position. The echo transducer
was placed on the left hemithorax and short axis views were
recorded. Two-dimensional images were obtained at midpapillary
level [20, 21]. M-mode tracing of left ventricular (LV) contrac-
tion was obtained at the same level as the short-axis view. LV
end diastolic diameter (LVEDD) and LV end systolic diameter
(LVESD) were measured with M-mode tracing. Percent fractional
shortening (% FS) was determined using [(LVEDD  LVESD)/
LVEDD]  100(%). LV end diastolic volume (LVEDV) was cal-
culated as 7.0  LVEDD3/ (2.4 þ LVEDD), LV end systolic vol-
ume (LVESV) as 7.0  LVESD3/(2.4 þ LVESD) and LV ejec-
tion fraction (EF) as EF(%) ¼ (LVEDV  LVESV)/LVEDV 
100. Two images per view were obtained and each parameter
was measured from three consecutive beats per image. Six values
of each parameter were obtained and averaged. Echocardiograms
were stored digitally and analyzed with EchoPAC with custom 2-
D strain rate imaging software. More than three images were
obtained in the short axis view and the parameters were measured
from three consecutive beats in each image. For quantitative anal-
ysis of regional LV systolic function, peak systolic circumferen-
tial strain and peak systolic radial strain were measured on six
segments (anteroseptum, anterior, anterolateral, posterolateral, in-
ferior, inferoseptum) of the mid LV level in the parasternal short-
axis view. For quantitative analysis of global LV systolic func-
tion, the average values of peak systolic circumferential and peak
systolic radial strain of the six segments were calculated.
Statistical Analysis
Results are expressed as mean  SEM. Statistical comparisons
between the two groups were performed using the Student’s t
test. In addition, a one-way ANOVA using a Bonferroni test was
used when comparing more than two groups. A p-value < .05
was considered signiﬁcant.
RESULTS
Kinetics of Hph-1-Hsp70 Delivery into MSCs and
Hsp70 Expression Under Hypoxic Conditions
MSCs were isolated from mixed culture with hematopoietic
cells based on their attachment to the culture plate, and fur-
ther puriﬁed by exclusion with magnetic beads targeting the
hematopoietic marker CD34. Yield was 3  106 cells (95%
purity) after 2 weeks of culture. Consistent with a previous
report [19], the cultured MSCs expressed CD71, CD90,
CD105, CD106, and ICAM, but not the hematopoietic
markers CD34 and CD14 (data not shown). For direct deliv-
ery of Hsp70 protein into MSCs, Hph-1-Hsp70 fusion protein
was generated and puriﬁed as a single band (data not shown).
After pretreatment of MSCs with Hph-1-Hsp70 protein for 1-
hour under normal culture conditions, Hph-1-Hsp70 protein
was readily delivered into MSCs and detected in the cyto-
plasm in less than 30 minutes, reaching a maximal intracellu-
lar concentration before 120 minutes. The delivery kinetics of
Hph-1-Hsp70 were dose- and time-dependent (Fig. 1A). The
delivered protein was observed in the cytoplasm and the nu-
cleus, and intracellular Hph-1-Hsp70 protein was observed for
more than 12 hours (supporting information Fig. 1B). As
demonstrated in our previous report [18], 12 hours of Hph-1
fusion protein in the cells was sufﬁcient to provide over 5
days of in vivo functional effectiveness to a fusion-protein
partner. To investigate whether hypoxia modulated Hsp70 in
MSCs, cells were exposed to hypoxia for varying periods.
Expression of Hsp70 increased after 1-hour of hypoxia, but
decreased after 6-hour, and was eventually strongly downre-
gulated (supporting information Fig. 2). These data suggest
that the substantial cell death of MSCs following prolonged
hypoxia could be due to a decrease in Hsp70 expression.
Anti-Apoptotic Effects of Delivered Hsp70 on MSCs
in Hypoxic Conditions
The survival rate of MSCs after 24 hours in hypoxic condi-
tions is normally 70% lower than MSCs cultured in normoxic
conditions. Hph-1-Hsp70 treatment enhanced the survival rate
of MSCs by about 65% compared to untreated MSCs (Nor-
moxia vs. Hypoxia: 1.09  0.10 vs. 0.32  0.04, p < .001;
Hph-1-Hsp70 vs. Hypoxia: 0.92  0.06 vs. 0.32  0.04, p <
.001) (Fig. 1B). In addition, the survival rate after prolonged
hypoxic stress (24–72 hours) was higher for Hph-1-Hsp70-
treated MSCs than Hph-1-treated MSCs (supporting informa-
tion Fig. 3). To further conﬁrm the effect of delivered Hph-1-
Hsp70 on apoptosis of MSCs under hypoxic conditions, we
analyzed the level of caspase-3 activity in MSCs delivered
with Hph-1-Hsp70 into after hypoxic incubation. Hypoxia
induced a 2.8-fold increase in caspase-3 activity, but activity
in Hph-1-Hsp70-treated MSCs was reduced signiﬁcantly after
24 hours of hypoxia (Normoxia vs. Hypoxia: 0.1  0.01 vs.
0.28  0.05, p < .001; Hph-1-Hsp70 vs. Hypoxia: 0.14 
0.04 vs. 0.28  0.05, p < .05) (Fig. 1C). Depletion of ATP is
the earliest cell-damaging factor after ischemic insult. Accord-
ingly, we analyzed the cellular ATP level of MSCs treated
with Hph-1-Hsp70 under hypoxic conditions. Hypoxic stress
caused a signiﬁcant decrease in cellular ATP of about 65%,
compared to normoxic culture MSCs. Delivery of Hph-1-
Hsp70 effectively protected MSCs from ATP depletion under
hypoxic conditions (Normoxia vs. Hypoxia: 800  56 vs. 280
 16, p < .001; Hph-1-Hsp70 vs. Hypoxia: 704  88 vs. 280
 16, p < .001) (Fig. 1D). In addition, intracellular Hph-1-
Hsp70 substantially increased expression of anti-apoptotic
protein Bcl-2 and decreased expression of the pro-apoptotic
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Figure 1. Anti-apoptotic Effects of Delivered Hsp70 on MSCs in Hypoxic Conditions. (A) Delivery kinetics of Hph-1-Hsp70 protein into
MSCs. MSCs were incubated in 1% FBS DMEM culture medium containing Hph-1-Hsp70 (0.1-2 lM) for 1-hour. The delivered Hsp70 in MSCs
was detected by Western blot. (B) Viability of MSCs. MSCs (1.5  104) were seeded in 96-well plates and cultured for 24 hours. MSCs were
treated with 0.5 lM Hph-1-Hsp70 fusion protein and simultaneously exposed to hypoxic or normoxic conditions for 24 hours. WST-1 reagent
was added to each well for 3 hours at 37C. Cell proliferation was measured by spectrophotometry (k ¼ 570 nm) (*p < .001). (C) Caspase-3
activity of MSCs. MSCs (1  106) were seeded in 60 mm plates and cultured for 24 hours. MSCs were pretreated with 0.5 lM Hph1-Hsp70
fusion protein followed by 24 hours of hypoxia or normoxia. Caspase-3 activity was measured as described in Materials and Methods (*p <
.001, **p < .05). (D) Intracellular ATP level of MSCs. MSCs (1.5  104) were plated into 96-well plates and cultured for 24 hours. After pre-
treatment with 0.5 lM Hph-1-Hsp70 fusion protein and hypoxic or normoxic incubation for 24 hours, nucleotide-releasing reagent and ATP-mon-
itoring reagent were added into each well, luminescence measured by luminometer (*p < .001). (E) Apoptosis-related signals in MSCs. MSCs
were treated with 0.5 lM Hph-1-Hsp70 and subjected to hypoxia or normoxia. After 6 hours, cells were harvested and b-actin, Bcl-2, Bax, JNK,
and phospho-JNK levels determined by immunoblotting (*p < .001). (F) Representative ﬂow cytometry of annexin V binding versus propidium
iodide (PI) uptake (A–D) and regional cell percentage (E) in MSCs at 24 hours after hypoxia. R1-4 represent the percentage of damaged,
necrotic, live, and apoptotic cells, respectively (*p < .01 vs. MSCþhypoxia, **p < .001 vs. MSC þ hypoxia).
protein Bax (Hph-1-Hsp70-Hypoxia vs. Hph-1-Hypoxia: 2.4
 0.08 vs. 0.62  0.09, p < .001). Phosphorylation of JNK
was also signiﬁcantly inhibited by Hph-1-Hsp70 (Hph-1-
Hsp70-Hypoxia vs. Hph-1-Hypoxia: 0.5  0.04 vs. One.03 
0.07, p < .001) (Fig. 1E). Figure 1F shows a representative
analysis and regional percentage of annexin V versus PI dot
plot of MSC, with and without Hph-1-Hsp70, in hypoxia or
normoxia. After pretreatment with Hph-1-Hsp70, the percent-
age of damaged, necrotic, and apoptotic cells in the R1, R2,
and R4 areas decreased compared to the hypoxia control
group (R1. Hypoxia vs. Hph-1-Hsp70: 21.36  0.36 vs.
Seven.84  0.34, p < .01; R2. Hypoxia vs. Hph-1-Hsp70:
9.41  0.12 vs. Seven.99  0.21, p < .01; R4. Hypoxia vs.
Hph-1-Hsp70: 15.55  0.45 vs. One.66  0.48, p < .001; R1
þ R2 þ R4. Hypoxia vs. Hph-1-Hsp70: 46.32  0.47 vs.
17.49  0.38, p < .001). These results demonstrate that deliv-
ery of Hph-1-Hsp70 effectively enhances viability of MSCs.
Improved Myocardial Repair After
Hsp70-MSC Implantation
To investigate the in vivo therapeutic efﬁcacy of Hph-1-
Hsp70-MSCs in myocardial infarction, we transplanted Hph-
1-, or Hph-1-Hsp70-MSCs, or MSCs labeled with DAPI into
the border region between the infarcted and normal area of
the heart after coronary ligation. After 3 days, hearts were
removed and the fate of the MSCs was investigated using
confocal microscopy. A higher number of Hph-1-Hsp70-
MSCs was retained in the border region than control MSCs
(Hph-1-Hsp70-MSC vs. MSC: 731  42 vs. 212  49, p <
.001) (Fig. 2A). In addition, time course experiments indi-
cated enhanced survival of Hph-1-Hsp70-treated MSCs com-
pared to non-treated MSCs (supporting information Fig. 4).
One week after coronary ligation, the size of the left ventricu-
lar infarct was evaluated in the transplanted and untreated
groups. The degree of ﬁbrosis in the infarct zone was substan-
tially higher in MSC-transplanted group than in the Hph-1-
Hsp70-MSC-transplanted group (Control vs. MSC: 39.5 
10.39 vs. 18.47  1.03, p < .01; MSC vs. Hph-1-Hsp70-
MSC: 18.47  1.03 vs. Nine.31  1.67, p < .05; control vs.
Hph-1-Hsp70-MSC: 39.5  10.39 vs. Nine.31  1.67, p <
.001) (Fig. 2B). To conﬁrm that the implanted cells had
become cardiac myocyte-like cells, cardiac-speciﬁc markers
were examined by immunohistochemistry. CTnT, MHC, and
MLC were detected in the DAPI-positive cells. DAPI-stained
Hph-1-Hsp70-MSCs also expressed connexin-43 and N-cad-
herin in the regions with the host cardiomyocytes, indicating
that DAPI-labeled donor cells were well-incorporated into the
non-labeled cells (host cardiomyocytes) (Fig. 2C). And, we
determined the infarct sizes in the left ventricle (LV) using
TTC staining. Injection of Hph-1-Hsp70-MSCs signiﬁcantly
decreased in infarct size compared to MSCs only or Hph-1-
MSCs (Control vs. Hph-1-MSC: 29.89  2.5 vs. 12.43 
2.51, p < .001; control vs. Hph-1-Hsp70-MSC: 29.89  2.5
vs. Six.12  1.38, p < .001; Hph-1-MSC vs. Hph-1-Hsp70-
MSC: 12.43  2.51 vs. Six.12  1.38, p < .05; MSC vs.
Hph-1-Hsp70-MSC: 15.03  1.49 vs. Six.12  1.38) (Fig.
3A). The incidence of TUNEL-positive myocardial cells was
signiﬁcantly reduced by 19.5  2.1% in the ligated hearts
transplanted with Hph-1-Hsp70-MSCs compared to control
(Control vs. Hph-1-Hsp70-MSC: 24.9  0.9% vs. Five.4 
1.2%, p < .001; MSC vs. Hph-1-Hsp70-MSC: 15.8  2.5%
vs. Five.4  1.2%, p < .05) (Fig. 3B). The mean microvessel
count per ﬁeld in the infarcted myocardium was signiﬁcantly
higher in the Hph-1-Hsp70-MSCs group than in other groups
(Control vs. Hph-1-Hsp70-MSC: 21  5 vs. 122  13, p <
.001; MSC vs. Hph-1-Hsp70-MSC: 75  12 vs. 122  13,
Figure 2. Changes in Representative Histological Sections after
Hsp70-MSC Implantation. (A) Detection of viable MSCs in ligated
hearts by Hph-1-Hsp70 pretreatment. Three days after implantation of
DAPI-labeled MSCs into MI-induced animal, DAPI-labeled cells
were observed by ﬂuorescence microscope (*p < .001). Scale bar:
100 lm. (B) Change of morphology in ligated heart by Hph-1-Hsp70
pretreatment. Top panel: Whole heart was harvested 7 days after
implantation of MSCs and H&E stained. Bottom panel: Masson’s
Trichrome stain of the infarcted region showing blue coloration of
ﬁbrotic areas, and orange/brown muscle tissue. H&E staining of the
inﬁltration of viable, mature cardiac myocytes from the border zone
into the scar area (*p < .001 vs. MSCs, ¶p < .05 vs. MSCs, #p <
.001 vs. control). Scale bar: H&E (2 mm), Trichrome: (100 lm). (C)
Enhanced potential for differentiation and integration of MSCs by
Hph-1-Hsp70 pretreatment. DAPI-labeled MSCs on the contact sur-
face with host myocytes were analyzed for cardiac-speciﬁc markers
cardiac troponin T (cTnT), MHC, MLC, connexin-43 (green), N-cad-
herin (green), or cTnT (red) by immunohistochemical staining. Scale
bar: H&E (150 lm), immunohistological staining: (50 lm).
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p < .05) (Fig. 3C). To conﬁrm generation of tumor in heart
implanted MSCs, cells (2.0  104 cells/ll) were directly
injected from the injured region to the border using a Hamil-
ton syringe (direct injection in the ventricular wall). There
was no tumor formation in heart including other organs (data
not shown).
Effective Improvement of Cardiac Function by
Implantation of Hph-1-Hsp70-MSCs
To examine the functional improvement fostered by Hph-1-
Hsp70-MSCs transplantation, cardiac dimensions and
performance parameters were measured by transthoracic
echocardiography. At baseline (i.e., after infarction and
before cell transplantation), echocardiographic parameters
were not signiﬁcantly different between the control groups.
Implantation of MSCs and Hph-1-Hsp70-MSCs showed
further improvement in systolic performance (FS of Control
vs. Hph-1-Hsp70-MSC: 14.63  2.22 vs. 27.99  3.04, p <
.01), cardiac dimensions (LVEDV of Control vs. Hph-1-
Hsp70-MSC: 0.84  0.07 vs. 0.53  0.08, p < .01), and
strain (Peak S rad of Control vs. Hph-1-Hsp70-MSC: 3.91
 1.07 vs. 20.04  1.84, p < .01) compared to control.
However, cardiac dimensions including LVEDD (Control vs.
Hph-1-Hsp70-MSC: 7.21  0.50 vs. Five.62  0.40, p <
.01) and LVESD (Control vs. Hph-1-Hsp70-MSC: 6.11 
0.38 vs. Three.71  0.36, p < .01) were substantially
smaller in the Hph-1-Hsp70-MSCs–treated group compared
to the MSCs-treated group (Table 1). Transplantation of
Hph-1-Hsp70-MSCs resulted in a further increase in systolic
performance (37.7% increment in % FS and 28.7% incre-
ment in % EF) compared to the MSCs-transplanted group.
The peak circumferential and radial strain on the infarct
zone and the global circumferential and radial strain were
signiﬁcantly higher in the Hph-1-Hsp70-MSCs group than
other groups (Fig. 4).
DISCUSSION
Irreversible tissue damage and physiologic dysfunction occur
in the heart as a consequence of myocardial infarction [22].
Recent attempts to repair infarcted hearts using alternative
sources of cardiomyocytes revealed that myogenic cells from
various stem cells replaced resident myocytes in cardiac tissue
after injury [23]. Attempts at postinfarct stem cell
Figure 3. Improved Myocardial Repair
after Hsp70-MSC Implantation. (A) Intra-
myocardial injection of MSCs reduced the
left ventricular (LV) infarct size as assessed
by TTC staining at 7 days post-MI. Hph-1-
Hsp70-MSCs further decreased the area of
necrotic tissue (*p < .001 vs. control, ¶p <
.05 vs. Hph-1-MSCs, #p < .001 vs. Hph-1-
Hsp70-MSCs). (B) Apoptosis assay on
heart tissue, 1 week after LAD ligation.
The left panel shows representative
TUNEL staining images (magniﬁcation:
200). Staining for normal nuclei (green)
using methyl green. Apoptotic nuclei are
brown. The right panel shows summarized
data from the left panel (*p < .05 vs.
MSCs, ¶p < .001 vs. control, #p < .01 vs.
Hph-1-MSCs). Scale bar: 100 lm. (C)
Quantitative analysis with microvessel den-
sity signiﬁcantly higher in Hsp70-MSC
groups than in MSC and control groups.
Brown: positive staining for CD31 (*p <
.001 vs. MSCs, ¶p < .05 vs. control, #p <
.01 vs. Hph-1-MSCs). Scale bar: 100 lm.
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transplantation therapy in the myocardium show a poor rate
of survival, however [24]. Cell death is inﬂuenced by an is-
chemic environment that is devoid of nutrients and oxygen
[12], coupled with the loss of survival signals because of
inadequate interaction between cells and matrix [25].
Recently, enhancing the viability of MSCs by introduction of
the Akt survival signal was used as a new approach in the
early post-transplant period, and resulted in improvement in
the regeneration of infarcted myocardium [13].
Heat shock protein (Hsp) is synthesized transiently as a
tool to protect cellular homeostasis after exposure to heat and
potentially deleterious stimuli. Hsp70 also inhibits apoptosis
in a caspase-independent manner [26]. This is likely to
involve Hsp70 inhibition of JNK, which plays a key role in
Figure 4. Effective Improvement of Cardiac Function by Implantation of Hph-1-Hsp70-MSCs. Cardiac functions were measured by two-dimen-
sional conventional parameters, fractional shortening (FS), and LV ejection fraction (EF) 3 weeks after injection of MSCs in IM-induced rats.
M-mode tracing of LV contraction was obtained at the same level as the short-axis view. LVEDD and LVESD were measured with M-mode
tracing. Percent fractional shortening (% FS) was determined as [(LVEDD  LVESD)/LVEDD]  100(%). LV end diastolic volume (LVEDV)
was calculated as 7.0  LVEDD3/ (2.4 þ LVEDD), LV end systolic volume (LVESV) as 7.0  LVESD3/(2.4 þ LVESD) and LV ejection frac-
tion (EF) as EF (%) ¼ (LVEDV  LVESV)/LVEDV  100 (*p < .01, **p < .05).
Table 1. Echo-data for untreated control, MSCs-treated, Hph-1-MSCs, and Hph-1-Hsp70-MSCs- treated rats
Variables Normal (n ¼ 8) Control (n ¼ 8) MSCs (n ¼ 8)
Hph-1-MSCs
(n ¼ 8)
Hph-1-Hsp70-MSCs
(n ¼ 8)
LVEDD (mm) 5.51  0.31 7.21  0.50 6.72  0.52a 6.64  0.48a 5.62  0.40a,b,c,d
LVESD (mm) 3.31  0.22 6.11  0.38 5.35  0.50a 5.28  0.29a 3.71  0.36a,b,c,d
FS (%) 39.64  5.54 14.63  2.22 20.33  1.95a 20.15  2.90a 33.98  3.04a,b,c,d
LVEDV (ml) 0.43  0.03 0.84  0.07 0.69  0.19a 0.66  0.10a 0.53  0.08a,b,c,d
LVESV (ml) 0.17  0.03 0.54  0.08 0.37  0.12a 0.35  0.09a 0.21  0.07a,b,c,d
LVEF (%) 68.5  6.1 35.5  4.8 47.0  3.7a 46.7  5.3a 60.5  4.1a,b,c,d
Peak S cir (%) (infarct zone) 7.81  1.14 1.90  0.40 4.31  1.72a 4.79  1.20a 6.60  1.25a,d,e,f
Peak S rad (%) (infarct zone) 24.23  1.92 3.91  1.07 16.33  1.40a 16.97  1.97a 20.04  1.84a,b,c,d
Global S cir (%) 20.32  1.64 4.23  1.63 7.64  1.27a 8.10  2.31a 12.05  1.40a,d,e,f
Global S rad (%) 38.23  4.42 5.58  2.42 25.14  3.65a 26.00  3.81a 31.81  3.75a,d,e,f
Values are mean  S.D.
ap < 0.01 vs. control, bp < 0.05 vs. MSCs, cp < 0.05 vs. Hph-1-MSCs, dp < 0.05 vs. normal, ep < 0.01 vs. MSCs, fp < 0.01 vs.
Hsp70-SCs.
Abbreviations: LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; FS, fractional shortening;
LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; MSCs, mesenchymal stem cells; S cir,
circumferential strain; S rad, radial strain.
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inducing apoptotic cell death in response to speciﬁc stimuli
[27, 28]. Mechanistic studies in non-cardiac cells on the in-
hibiting effect of Hsp70 on pro-apoptotic mechanisms parallel
the direct demonstration that over-expression of Hsp70 can in-
hibit apoptosis in implanted MSCs [9].
Despite accumulating evidence on the protective role of
Hsp70, many problems remain in direct gene delivery to the
heart for cardiac protection, similar to all gene therapy proce-
dures [9, 15, 16, 29]. As described above, genetic manipula-
tion of cells by transfection or viral introduction of cDNA
expression vectors and microinjection of proteins into cells
presents various difﬁculties, including low transfection efﬁ-
ciency and cytotoxicity from chemical agents and harmful vi-
ral transfection [15–17]. In this study, we synthesized Hsp 70
fusion proteins with Hph-1-PTD, a peptide capable of freely
transducing bound proteins into cells. TAT, an HIV-derived
PTD that can cross cell membranes, was discovered in 1988
by two independent groups [30, 31]. Our previous report iden-
tiﬁed a novel cell-permeable PTD from the human transcrip-
tional factor Hph-1, and successfully delivered Hph-1-PTD
immunosuppressive proteins in vivo and in vitro through dif-
ferent administration routes, for the treatment of various auto-
immune diseases [18]. This work on myocardial repair aims
to overcome the problem of cell death after implantation by
improving cell viability with MSCs delivered with Hph-1-
Hsp70.
Hph-1-Hsp70-MSCs showed a remarkable increase in sur-
vival under hypoxic conditions. In addition, we observed that
JNK phosphorylation, caspase-3 and pro-apoptotic Bax
decreased signiﬁcantly. We also conﬁrmed increases in levels
of anti-apoptotic Bcl-2. Any form of cell injury, as well as is-
chemia, results in a rapid decrease in cytoplasmic ATP levels.
Kabakov et al. [32] reported that Hsp70 overexpression
attenuates proteotoxicity of cellular ATP depletion. We also
observed that delivery of Hph-1-Hsp70 attenuated ATP deple-
tion in MSCs under hypoxic conditions. After pretreatment
with Hph-1-Hsp70, the percentage of damaged, necrotic, and
apoptotic cells decreased compared to the hypoxia control
group. According to our in vivo histological ﬁndings, trans-
plantation of Hph-1-Hsp70-MSCs resulted in a further
decrease in infarct size and improvement of microvessel den-
sity. Indeed, improvement in cardiac structure was related
with reduction of ﬁbrotic area and infarct size, higher capil-
lary density. Especially, Hph-1-Hsp70-MSCs-mediated
increase in microvessel formation may increase blood ﬂow
within the infarcted area and contribute to inhibition of car-
diac remodeling, and subsequent improvement in systolic
function. Moreover, transplantation of Hph-1-Hsp70-MSCs
into infarction-induced animals signiﬁcantly improved heart
function assessed by various parameters. Neither cytotoxic
effects on MSCs with signiﬁcantly higher concentrations of
Hph-1-Hsp70 nor tumorigenesis of Hph-1-Hsp70-treated
MSCs were detected (data not shown), and behavioral abnor-
malities were not observed in mice implanted with Hph-1-
Hsp70-MSCs. According to transthoracic echocardiography,
transplantation of Hph-1-Hsp70-MSCs was decreased in
LV chamber size, and improved LV systolic function. These
functional parameters of the heart showed functional
and structural improvement following Hph-1-Hsp70-MSCs
transplantation.
CONCLUSION
In this report, we demonstrate that modiﬁcation of MSCs by
Hph-1-Hsp70 effectively protected MSCs from in vitro and in
vivo cell death caused by different mechanisms of apoptosis
under hypoxic conditions, leading to improved MSC cell via-
bility. Hph-1-Hsp70-MSCs retained function in the infarcted
region of the myocardium and promoted the expression of
cardiac-speciﬁc markers on MSCs. Transplantation of Hph-1-
Hsp70-MSCs into infarction-induced animals signiﬁcantly
improved LV function, limited LV remodeling, and changed
heart structure after myocardial infarction assessed by various
parameters. Our results suggest that enhancing the viability
and integration potential of MSCs by Hph-1-Hsp70 treatment
before transplantation provides novel therapeutic opportunities
for the treatment of myocardial infarction and end-stage car-
diac failure.
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